{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:35Z","timestamp":1790050895892,"version":"4.0.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.2217\/fon-2020-0023","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T14:38:48Z","timestamp":1583246328000},"page":"619-629","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Vorinostat in patients with resistant\n            <i>\n              BRAF\n              <sup>V600E<\/sup>\n            <\/i>\n            mutated advanced melanoma: a proof of concept study"],"prefix":"10.1080","volume":"16","author":[{"given":"Sanne","family":"Huijberts","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Molecular Carcinogenesis, Oncode Institute,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Leite","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Division of Molecular Carcinogenesis, Oncode Institute,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"Nuijen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"},{"name":"Department of Pharmacy &amp; Pharmacology,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"},{"name":"Faculty of Science,Utrecht University,\rUniversiteitsweg 99,\r3584 CG\rUtrecht,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Bernards","sequence":"additional","affiliation":[{"name":"Division of Molecular Carcinogenesis, Oncode Institute,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"},{"name":"Faculty of Science,Utrecht University,\rUniversiteitsweg 99,\r3584 CG\rUtrecht,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schellens","sequence":"additional","affiliation":[{"name":"Faculty of Science,Utrecht University,\rUniversiteitsweg 99,\r3584 CG\rUtrecht,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Wilgenhof","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,The Netherlands Cancer Institute,\rPlesmanlaan 121,\r1066CX\rAmsterdam,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"e_1_3_6_3_1","unstructured":"ECIS \u2013 European Cancer Information System . European Cancer Information System (2019). http:\/\/ecis.jrc.ec.europa.eu\/explorer"},{"key":"e_1_3_6_4_1","unstructured":"Wolter K . Molecularly targeted therapies for metastatic melanoma (2019). www.uptodate.com"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1085509"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112302"},{"key":"e_1_3_6_8_1","unstructured":"Werkgroep NM . Concept richtlijn melanoom (2012). www.oncoline.nl\/uploaded\/docs\/melanoom\/CONCEPT%20richtlijn%20melanoom.doc.pdf"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.05.012"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09626"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.04.012"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.01.009"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.02.045"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S29965"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.09.003"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.1291"},{"key":"e_1_3_6_18_1","unstructured":"US FDA . FDA approval Zolinza (vorinostat); prescribing information (2008)."},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.014"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30171-7"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2220-z"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5788"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.06.030"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep11198"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.167"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01237.x"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2307"},{"issue":"10","key":"e_1_3_6_29_1","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly WK","year":"2003","unstructured":"Kelly WK , RichonVM, O\u2019ConnorOet al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res.9(10 Pt 1), 3578\u20133588 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0348-6"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13574"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00990"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1412064"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2923"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.10"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:09Z","timestamp":1719125169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.2217\/fon-2020-0023"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0023","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}